3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Brand Engagement Network Inc. entered a settlement agreement with Evora Partners on September 30, 2026, to resolve about $1.3 million it owed under a January 2021 consulting agreement. Evora agreed to accept $825,000, including a $75,000 reimbursement of attorneys' fees, and will dismiss its pending lawsuit against the company. The deal resolves a liability already recorded in accounts payable and removes the pending litigation.
Settlement amount is $825,000, including a $75,000 reimbursement of Evora's attorneys' fees, against about $1.3 million owed.
The company has paid $175,000; the remaining $650,000 is due in installments through December 2026, guaranteed by BEN Capital Fund I, LLC.
Evora will dismiss its lawsuit filed September 2, 2026, in the U.S. District Court for the Southern District of New York.
Opus Genetics presented interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy trials at Retina in Rio 2026 on October 14, 2026, and furnished the press release and slides in this 8-K. The company said the data are interim and based on small participant groups, and it expects Phase 3 dosing for OPGx-LCA5 to begin in the fourth quarter of 2026.
OPGx-BEST1 low-dose Cohort 1: three of four evaluable participants (75%) showed improved retinal sensitivity in the treated transitional zone.
OPGx-LCA5 adults showed sustained improvements in visual acuity and light sensitivity through 24 months; three pediatric participants showed results through six months.
OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.
Varonis Systems agreed to be acquired by Proofpoint, a Thoma Bravo portfolio company, in an all-cash transaction valued at about $6.3 billion. Varonis shareholders would receive $49.75 per share, a 52% premium to the June 22, 2026 closing price of $32.71, and the deal requires shareholder and regulatory approval, with closing expected in the first half of 2027. Varonis shares would stop trading on Nasdaq and the company would become private.
Merger consideration of $49.75 per share in cash, a 52% premium to the $32.71 close on June 22, 2026 and 17% above the $42.35 close on September 1, 2026
Transaction valued at about $6.3 billion, or about 53x LTM free cash flow and 8.4x LTM revenue
Varonis must pay Proofpoint a $211.7 million termination fee in specified circumstances; Proofpoint would pay a $423.3 million reverse termination fee in specified circumstances
Expected to close in the first half of 2027; either party may terminate if the merger is not completed by July 15, 2027, subject to a three-month regulatory extension
Biohaven entered into a Collaboration and License Agreement with Ono Pharmaceutical dated October 8, 2026, granting Ono an exclusive, royalty-bearing license to develop and commercialize its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and the ASEAN countries. Biohaven retains rights outside that territory, including the United States, Europe and China. The deal provides Biohaven up to $100 million in near-term payments, which the company says is non-dilutive capital.
Ono pays a one-time, non-refundable upfront payment of $80 million upon closing.
Biohaven is eligible for another $20 million upon a milestone, tied to Ono's stability test results and its election to continue development; the press release anticipates this milestone within a year.
Ono will pay royalties of approximately 20% on net sales of licensed products in the licensed territory, subject to specified reductions.
Ono may terminate the agreement for convenience on specified prior written notice, in whole or by product or country.
J.B. Hunt Transport Services reported third quarter 2026 results for the period ended September 30, 2026, with total operating revenue up 20% to $3.68 billion and diluted earnings per share of $1.82 versus $1.76 a year earlier. Operating income rose 2% to $247.1 million, but operating income as a percentage of gross revenue declined, and the company cited higher purchased transportation, fuel costs and insurance claims.
Q3 2026 total operating revenue was $3.68 billion, up 20%; revenue excluding fuel surcharge rose 13%.
Net earnings were $172.4 million versus $170.8 million a year earlier; diluted EPS was $1.82 versus $1.76.
Operating income was $247.1 million, up 2%; Dedicated Contract Services operating income fell 22% to $81.7 million.
In the third quarter the company bought back about 704,000 shares for about $174 million and had about $619 million left under its repurchase authorization.
Blue Owl Finance LLC, an indirect subsidiary of Blue Owl Capital Inc., signed a fourth amendment to its credit agreement on October 14, 2026. The revolving credit commitment rises to $3,225,000,000 (potentially $3,870,000,000 if conditions are met), the maturity is extended to October 14, 2031, and pricing is reduced, which lowers borrowing costs for the subsidiary.
Revolving commitment increased to $3.225 billion, with a potential increase to $3.87 billion if conditions are satisfied
Maturity extended from the existing date to October 14, 2031
Term SOFR loan margin reduced to 77.5 to 127.5 basis points; commitment fee rate reduced to 7.0 to 16.5 basis points
MUFG Bank, Ltd. serves as administrative agent; the Company itself is not a party to the amended agreement
The Charles Schwab Corporation reported third-quarter 2026 results for the quarter ended September 30, 2026, in an 8-K furnishing its earnings press release as Exhibit 99.1. Net revenues rose 17% year-over-year to a record $7.2 billion, and GAAP diluted earnings per share rose 29% to $1.62 from $1.26. The results show growth in both revenue and profit, while GAAP results include $151 million of pre-tax transaction-related costs that the company excluded from its adjusted figures.
Net income was $2.9 billion for the quarter, up 23% from $2.4 billion a year earlier; adjusted diluted EPS was $1.69.
Core net new assets were $190.4 billion, up 38% versus the third quarter of 2025.
Pre-tax transaction-related costs totaled $151 million; the company also hosted a Fall Business Update for institutional investors on October 15, 2026.
NB Bancorp, Inc., the holding company for Needham Bank, reported third quarter 2026 net income of $23.1 million, or $0.58 per diluted share, up from $21.1 million, or $0.53 per diluted share, in the prior quarter. Operating net income, a non-GAAP measure, was $23.8 million, or $0.60 per diluted share, while net charge-offs rose to 0.31% of average loans from 0.07%, mainly due to a $4.0 million charge-off. The Board also declared a $0.07 per share dividend.
Net income $23.1 million, or $0.58 per diluted share, versus $21.1 million, or $0.53, in the prior quarter
Net interest margin declined to 3.97% from 4.00%; total loans rose 5.3% in the quarter to $6.77 billion
Net charge-offs were $5.2 million, or 0.31% of average loans, including a $4.0 million charge-off on a previously reserved loan
Dividend of $0.07 per share is payable November 12, 2026, to shareholders of record as of October 29, 2026
Independent Bank Corp. reported third quarter 2026 net income of $89.7 million, or $1.90 per diluted share, up from $81.8 million, or $1.70 per share, in the second quarter. Higher net interest income drove the gain, while nonperforming loans rose to $125.7 million, mainly due to one office real estate loan.
Net income of $89.7 million versus $81.8 million in Q2 2026; diluted EPS of $1.90 versus $1.70
Net interest income rose $9.7 million to $220.7 million; net interest margin was 3.89%, up 4 basis points
Nonperforming loans increased to $125.7 million from $103.6 million, driven primarily by one office real estate loan
Repurchased about 679,000 shares for $57.4 million; about $93 million remains under the $200 million buyback plan
Consolidated Water's U.S. subsidiary, PERC Water, signed a fixed-price design-build agreement with the City of Pismo Beach, California, for an advanced water purification facility, with a contract price of approximately $39.8 million. The filing sets a Substantial Completion deadline of September 17, 2028, with liquidated damages and a $14.0 million cap on PERC's total liability, so the contract adds revenue but also carries schedule and performance obligations.
Agreement executed October 8, 2026; fixed design-build price of approximately $39.8 million, subject to adjustment.
Substantial Completion required within 703 calendar days, with a stated date of September 17, 2028; liquidated damages of $2,500 per day, capped at 5% of the contract price (about $2.0 million).
PERC's total aggregate liability is capped at $14.0 million; performance and payment bonds are each 100% of the contract price.
The 8-K describes initial capacity of 500 acre-feet per year, expandable to 750, while the October 12, 2026 press release describes annual capacity of approximately 750 acre-feet.
LCNB Corp. reported third-quarter 2026 net income of $7.3 million, up from $6.9 million a year earlier, and nine-month net income of $19.2 million, up from $17.5 million. Net interest margin widened to 3.92% from 3.57%, while non-interest income fell and nonperforming loans doubled from a year earlier, which bears watching for shareholders.
Q3 2026 net income was $7.3 million, or $0.51 per diluted share, versus $6.9 million, or $0.49, in Q3 2025.
Nine-month 2026 net income was $19.2 million, or $1.35 per share, versus $17.5 million, or $1.23, a year earlier.
Tax-equivalent net interest margin was 3.92% in Q3 2026 versus 3.57% a year earlier; non-interest income fell to $5.3 million from $5.7 million.
Nonperforming loans were $4.1 million, or 0.24% of total loans, at September 30, 2026, versus $2.0 million, or 0.12%, a year earlier.
Interactive Brokers reported third-quarter 2026 GAAP diluted EPS of $0.69, up from $0.59 a year earlier, and GAAP net revenues of $1.91 billion, up from $1.66 billion. The board also raised the quarterly cash dividend from $0.0875 to $0.15 per share, payable December 14, 2026, to holders of record on December 1, 2026.
GAAP diluted EPS was $0.69 versus $0.59 in the year-ago quarter; adjusted EPS was $0.67 versus $0.57.
GAAP net revenues were $1.91 billion versus $1.66 billion; net interest income rose 19% to $1.15 billion.
Pretax profit margin was 78% versus 79% a year earlier, both as reported and as adjusted.
Quarterly dividend increases from $0.0875 to $0.15 per share, payable December 14, 2026.
Westamerica Bancorporation reported third quarter 2026 net income of $28.2 million, or $1.22 per diluted share, up from $27.4 million and $1.17 in the second quarter. Compared with the third quarter of 2025, net income was down 0.4% while EPS rose 8.9%, reflecting a smaller share count after buybacks.
Q3 2026 net income $28.2 million versus $27.4 million in Q2 2026; diluted EPS $1.22 versus $1.17
Net interest margin (FTE) 3.81%, up 4 basis points from Q2 2026; no provision for credit losses recognized
Noninterest income $10.7 million, up from $10.3 million in Q2, partly due to a one-time termination fee
Company retired 51 thousand common shares and paid a $0.48 per share dividend in the quarter
Gulf Resources said it received approval from the Shouguang Municipal Government to resume production at its Factories No. 2 and No. 10. The company expects to complete test and trial production in the fourth quarter of 2026 and believes the factories will produce revenue in the first half of 2027.
Approval from the Shouguang Municipal Government to resume production at Factories No. 2 and No. 10, announced October 14, 2026
Preparation work, including upgrades to some facilities, to begin immediately, with test and trial production expected to be completed in Q4 2026
Revenue from the factories expected in the first half of 2027
Company states resumption would raise annual production capacity by more than 20%, citing its 2025 Form 10-K
Prologis reported third quarter 2026 results on October 15, 2026, with higher revenue, net earnings and Core FFO than a year earlier. The company also gave 2026 guidance of $6.25 to $6.29 per share for Core FFO, but the filing does not say whether that guidance changed from earlier levels.
Total revenues were $2.39 billion for the quarter ended September 30, 2026, up from $2.21 billion a year earlier.
Net earnings attributable to common stockholders were $816 million, or $0.86 per diluted share, compared with $763 million, or $0.82, in Q3 2025.
2026 guidance: Core FFO attributable to common stockholders/unitholders of $6.25 to $6.29 per share; net earnings of $4.05 to $4.15 per share.
Velo3D said preliminary, unaudited third-quarter 2026 revenue is expected to be $19.5 million to $20.5 million, up about 43% to 51% from $13.6 million a year earlier. The figures are unaudited, not yet reviewed by the auditor, and subject to change, and the company plans to release final results the week of November 9, 2026.
Preliminary Q3 2026 revenue range: $19.5 million to $20.5 million, versus $13.6 million in Q3 2025
Year-over-year growth of approximately 43% to 51%
Final Q3 2026 results expected the week of November 9, 2026; the auditor has not reviewed the preliminary figures
Forward-looking risks listed include the company's ability to continue as a going concern and to raise capital
SenesTech said preliminary unaudited revenue for the quarter ended September 30, 2026 was about $1.1 million, up about 40% from the second quarter of 2026 and about 55% from the third quarter of 2025. The company said this was its first quarter at or above $1 million in revenue, and it will release full third-quarter results the week of November 9, 2026, noting the figures may change after quarter-end procedures are completed.
Preliminary Q3 2026 revenue: about $1.1 million, versus the company's prior-quarter level and the Q3 2025 level as stated in the release
Growth: about 40% sequentially versus Q2 2026 and about 55% year over year versus Q3 2025
Management cited higher subscription revenue and e-commerce and B2B traction; full results due the week of November 9, 2026
Marsh reported third quarter 2026 results on October 15, 2026. Revenue rose 8% to $6.9 billion, or 5% on an underlying basis, and GAAP diluted EPS was $1.69 versus $1.51 a year earlier. Adjusted EPS rose 10% to $2.03, while nine-month GAAP diluted EPS fell to $6.68 from $6.75.
Q3 2026 revenue was $6.9 billion, up 8% from $6.4 billion, or 5% on an underlying basis.
Q3 GAAP diluted EPS was $1.69 versus $1.51; adjusted EPS rose 10% to $2.03.
Nine-month GAAP diluted EPS was $6.68 versus $6.75; nine-month adjusted EPS rose 9% to $8.29.
In Q3 the company repurchased 2.7 million shares for $500 million.
CMC reported fourth-quarter fiscal 2026 results for the period ended August 31, 2026. Net earnings were $212.5 million, or $1.91 per diluted share, up from $151.8 million, or $1.35 per share, a year earlier, and net sales rose 25.7% to $2.66 billion. For the first quarter of fiscal 2027, the company expects North America Steel adjusted EBITDA to be nearly flat with the fourth quarter and Construction Solutions Group adjusted EBITDA to decline sequentially.
Fourth-quarter net earnings of $212.5 million ($1.91 diluted EPS) vs. $151.8 million ($1.35) a year earlier; adjusted EPS was $2.09
Consolidated core EBITDA rose 35.1% year over year to $393.7 million, with a 14.8% margin
Precast adjusted EBITDA of $57.0 million fell below management's prior expectations due to regional residential softness; an unplanned Galvabar outage hurt Performance Reinforcing Steel
Quarterly dividend of $0.20 per share declared October 13, 2026, payable November 11, 2026
ManpowerGroup reported third-quarter 2026 revenue of $4.8 billion, up 4% as reported and 5% in constant currency, and diluted EPS of $0.71 versus $0.38 a year earlier. Charges reduced third-quarter EPS by $0.30, and excluding them EPS was $1.01. The company also guided fourth-quarter diluted EPS to $1.03 to $1.13 and said Becky Frankiewicz will become CEO on January 1, 2027, with Jonas Prising moving to Executive Chair.
Third-quarter net earnings were $34.1 million versus $18.0 million; operating profit was $82.3 million versus $66.6 million.
Fourth-quarter 2026 diluted EPS is expected between $1.03 and $1.13, with a 44% effective tax rate.
Nine-month net earnings were $90.1 million, or $1.89 per diluted share, compared with a net loss of $43.5 million a year earlier.
Becky Frankiewicz will become CEO on January 1, 2027, with Jonas Prising transitioning to Executive Chair.
Plug Power said preliminary, unaudited third-quarter 2026 revenue grew more than 10% from Q3 2025, and net cash usage was approximately $28 million. The company said it remains on track for its previously communicated full-year 2026 revenue growth guidance of approximately 15% to 16%, but the figures may change after quarter-end close and auditor review.
Preliminary Q3 2026 revenue growth greater than 10% versus Q3 2025, based on unaudited estimates
Net cash usage for Q3 2026 approximately $28 million; cash and cash equivalents approximately $134 million at quarter end
No proceeds raised through the at-the-market offering program or other equity or debt capital raises in Q3
Full-year 2026 revenue growth guidance of approximately 15% to 16% reiterated; Q3 earnings call set for November 9, 2026
Aquestive Therapeutics said the FDA has accepted its resubmitted New Drug Application for Anaphylm as complete and classified it as a Class 2 response, with a PDUFA goal action date of March 16, 2027. The filing does not provide financial figures, and the outcome depends on the FDA's review, which the company says it expects to complete on or before the goal date.
FDA acknowledged the Anaphylm NDA resubmission as complete and classified it as a Class 2 response
PDUFA goal action date set for March 16, 2027
Aquestive submitted the resubmission on September 16, 2026, after a January 30, 2026 Complete Response Letter
Ex-U.S. submission to Health Canada remains on track for Q4 2026
On October 15, 2026, BNY reported third-quarter 2026 results, with total revenue of $5.7 billion, up 12% from a year earlier and flat from the second quarter. Diluted EPS was $2.34, up 24% year over year but down 4% from $2.45 in the second quarter. The company returned $1.4 billion of capital to common shareholders, which matters to shareholders because it reflects both earnings growth and continued payouts.
Total revenue of $5.7 billion, up 12% year over year and flat from the second quarter ($5,698 million)
Diluted EPS of $2.34, up 24% from $1.88 a year earlier but down from $2.45 in the second quarter
Pre-tax operating margin of 38.5%, compared with 36.4% a year earlier and 39.8% in the second quarter
Returned $1.4 billion to common shareholders, including $937 million of share repurchases and $436 million of dividends
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.